FINWIRES · TerminalLIVE
FINWIRES

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

By

Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activity than a competing treatment and a "more convenient dosing profile," supporting the drug's potential as a best-in-class therapy, Morgan Stanley said in a report Monday.

Divesiran produced a 69% placebo-adjusted response rate across pooled treatment arms, compared with 44% for Protagonist Therapeutics' (PTGX) rusfertide, while offering dosing every six or 12 weeks versus once weekly for the competing therapy, the report said.

The investment bank also highlighted a favorable safety profile, with 91% of patients in the divesiran arms avoiding phlebotomy during the study and 44 of 48 people who completed the study choosing to enter the open label extension, according to the report.

Silence plans to present detailed Phase 2 data at the American Society of Hematology meeting in December, meet with the US Food and Drug Administration by the end of 2026 and begin a Phase 3 study in the first half of 2027, the report said.

Morgan Stanley reiterated its overweight rating on Silence Therapeutics and raised its price target to $32 from $25.

Price: $15.14, Change: $-0.29, Percent Change: -1.88%

Related Articles

Wire

Fermi Signs First Binding Lease Agreement at Project Matador in Texas; Shares Rise After Hours

Fermi (FRMI) said late Monday it has signed its first binding customer lease at its Project Matador campus in Texas, a deal expected to generate about $6.5 billion over its initial 15-year term for the first phase.The lease between Fermi's subsidiary Fermi Campus 1 and TensorWave TEX1, a unit of TensorWave, covers a facility supported by 222 megawatts of total power once the final delivery phase begins.The agreement includes expansion rights for two additional data centers that would bring the partnership to more than 650 MW if exercised.Project Matador's first power is targeted for 2026, with construction already underway and permits secured for about 6 GW of the planned 17-GW campus.Fermi shares jumped 19% in after-hours trading.

$FRMI
Wire

Everpure Secures Second Hyperscaler Design, Supply Agreement; Shares Rise After Hours

Everpure (P) secured a second design and supply contract with an undisclosed top-five hyperscaler.The first contract was announced in late 2024 and uses Everpure's advanced software-powered DirectFlash technology to optimize hyperscale storage.The latest contract will be a "significant contributor to future revenue" starting in fiscal 2028, the company said Monday in a statement.Everpure shares rose 7.7% in after-hours trading.

$P
Wire

Upwork Q2 Adjusted Earnings Rise, Revenue Declines; Shares Fall After-Hours

Upwork (UPWK) reported Q2 non-GAAP earnings late Monday of $0.41 per diluted share, up from $0.35 a year earlier.Analysts polled by FactSet expected $0.34.Revenue for the quarter ended June 30 was $191.7 million, down from $194.9 million a year earlier.Analysts expected $189.9 million.The company expects Q3 non-GAAP EPS of $0.31 to $0.33 on revenue of $176 million to $184 million. Analysts expect $0.41 and $193.8 million, respectively.The company now expects 2026 non-GAAP EPS of $1.38 to $1.43 on revenue of $730 million to $750 million. It previously expected non-GAAP EPS of $1.50 to $1.55 on revenue of $760 million to $790 million.Analysts expect $1.54 and $776.0 million, respectively.Upwork shares fell over 21% in after-hours trading.

$UPWK